This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Covis Pharma To Acquire US Rights From Sanofi For Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, And Kayexalate®

ZUG, Switzerland, April 4, 2013 /PRNewswire/ -- Covis Pharma Sarl ("Covis Pharma"), a Switzerland-based specialty pharmaceutical company today announced an agreement with sanofi-aventis U.S. LLC and certain of its affiliates ("Sanofi") to acquire full commercial rights for Nilandron® (nilutamide), Plaquenil® (hydroxychloroquine), Rilutek® (riluzole), Uroxatral® (alfuzosin hydrochloride), and Kayexalate® (sodium polystyrene sulfate) in the United States.  The aggregate sales for these products in the United States in 2012 were $114.6 million.  Sanofi will retain the existing rights for these products in countries outside the United States.  Terms of the agreement have not been disclosed.

"We are very pleased to announce the addition of these products to our existing portfolio," said Jack Davis, CEO of Covis Pharma.  "Covis will continue to supply consistent, top quality, branded pharmaceuticals, ensuring that patients receive the therapeutic care they need."  Covis Pharma will promote these branded products through its US-based distributor, Covis Pharmaceuticals Inc.   Covis Pharma also supplies authorized generic products to the US market through a separate distributor, Rising Pharmaceuticals Inc.  Sanofi will manufacture and supply the products for Covis Pharma.

The agreement has received Hart-Scott-Rodino regulatory clearance in the United States.

About Covis Pharma

Headquartered in Zug, Switzerland, Covis Pharma is a global specialty pharmaceutical company providing therapeutic solutions to patients.  The company's distinctive product portfolio addresses life threatening and other serious medical conditions.  With eleven branded products currently in market, Covis Pharma aims to become a leading specialty pharmaceutical company through organic, as well as global acquisitive, growth.  The investor group in Covis Pharma has significant investment and operational experience in the specialty pharmaceutical industry.  Led by affiliates of Cerberus Capital Management, L.P., one of the world's leading private investment firms, the investor group also includes Princeton Biopharma Capital Partners, LLC and Bourne Partners. For more information, visit  www.covispharma.com.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs